URGN
UroGen Pharma Ltd. Ordinary Shares
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
URGN Stock Analysis: Buy, Sell, or Hold?
$26.33
+0.23 (+0.88%)
▲
5d:
+2.33%
30d:
-28.02%
90d:
-45.4%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 04, 2026
0d
Protect URGN Gains
Updated Nov 12, 12:00 AM ET
QUANTITATIVE VERDICT
HOLD
LOW Confidence (91%)
Quality Score
61/100
Position
OVERSOLD
30-Day Fair Range
$31.60 – $40.21
Position: OVERSOLD
Forward P/E & Valuation
9.9x
CHEAP
vs 20.1x historical avg
Wall Street Target
$60.71
+132.6% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$24.40 / $34.97
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 HOLD: URGN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Get Alerted When URGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$74.43
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$46.22
43.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 20.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: URGN is currently trading at $26.33, which is considered oversold relative to its 30-day fair value range of $31.60 to $40.21. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.9) compared to its historical average (20.1). Remarkably, the market is currently pricing in an annual earnings decline of 21.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, URGN is in a strong uptrend. Immediate support is located at $24.40, while resistance sits at $34.97.
Market Sentiment: URGN scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $60.71 (+132.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, URGN is in a strong uptrend. Immediate support is located at $24.40, while resistance sits at $34.97.
Market Sentiment: URGN scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $60.71 (+132.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$31.60 -
$40.21
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
90.5%
Trading Range & Key Levels
30-Day Trading Range
$31.60 -
$40.21
Current vs Trading Range
OVERSOLD
Support Level
$24.40
Resistance Level
$34.97
Current Trend
Strong Uptrend
Technical data as of
Nov 12, 2026
Protect Your Profits
Holding URGN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 132.6% below Wall St target ($60.71)
- CAUTION: Bottoming setup, but lagging the sector by 19% over 20 days — wait for relative strength
Fundamental Context
Forward P/E (Next Year Est.)
9.88
Wall Street Target
$60.71
(+132.6%)
Revenue Growth (YoY)
223.9%
Profit Margin
-26.3%
Valuation Discount vs History
-21.0% cheaper
PE vs Historical
9.9 vs 20.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-21.0%
(market-implied from PE analysis)
1-Year Target
$23.49
(-10%)
2-Year Target
$21.14
(-19%)
3-Year Target
$19.03
(-27%)
3-Yr Target (if PE normalizes)
(PE: 10→20)
$38.73
(+48%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.9 to 20.1
Stabilization Target:
$53.12
(+103.5%)
PE Expansion Potential:
+103.5%
Share URGN Analysis
Share this live URGN analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (URGN)
Bullish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 10, 2026
Daily AI digest
AI Retail Discussion Summary:
One bullish trader on StockTwits expressed optimism for $URGN's stock price recovery.
Key Retail Themes:
recovery
positive sentiment
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 2:00 PM ET
Data refreshes hourly during market hours. Next update: 3:00 PM
Data refreshes hourly during market hours. Next update: 3:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is URGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$302 | 51 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$592 | 39 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$304 | 36 SELL |
|
ORIC
Oric Pharmaceuticals Inc |
STRONG BUY
15 analysts |
$22 | 67 BUY |
|
IDYA
Ideaya Biosciences Inc |
STRONG BUY
16 analysts |
$51 | 60 BUY |
Advanced URGN Option Strategies
Professional options setups generated by AI based on today's URGN price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive URGN Research Pages
